|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FLVCR1 |
Gene summary for FLVCR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FLVCR1 | Gene ID | 28982 |
| Gene name | FLVCR heme transporter 1 | |
| Gene Alias | AXPC1 | |
| Cytomap | 1q32.3 | |
| Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | B2RB38 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 28982 | FLVCR1 | HCC1_Meng | Human | Liver | HCC | 6.15e-53 | 1.53e-01 | 0.0246 |
| 28982 | FLVCR1 | HCC2_Meng | Human | Liver | HCC | 7.16e-14 | 7.41e-02 | 0.0107 |
| 28982 | FLVCR1 | HCC1 | Human | Liver | HCC | 1.67e-37 | 3.46e+00 | 0.5336 |
| 28982 | FLVCR1 | HCC2 | Human | Liver | HCC | 2.43e-59 | 4.12e+00 | 0.5341 |
| 28982 | FLVCR1 | HCC5 | Human | Liver | HCC | 3.25e-66 | 3.35e+00 | 0.4932 |
| 28982 | FLVCR1 | S014 | Human | Liver | HCC | 3.10e-02 | 1.62e-01 | 0.2254 |
| 28982 | FLVCR1 | S016 | Human | Liver | HCC | 1.95e-06 | 1.93e-01 | 0.2243 |
| 28982 | FLVCR1 | S028 | Human | Liver | HCC | 1.08e-14 | 5.03e-01 | 0.2503 |
| 28982 | FLVCR1 | S029 | Human | Liver | HCC | 1.58e-13 | 4.59e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000683912 | Liver | HCC | mitochondrial transport | 184/7958 | 254/18723 | 2.30e-22 | 3.83e-20 | 184 |
| GO:000170111 | Liver | HCC | in utero embryonic development | 204/7958 | 367/18723 | 2.44e-07 | 4.30e-06 | 204 |
| GO:003410122 | Liver | HCC | erythrocyte homeostasis | 79/7958 | 129/18723 | 1.32e-05 | 1.47e-04 | 79 |
| GO:000226222 | Liver | HCC | myeloid cell homeostasis | 93/7958 | 157/18723 | 1.67e-05 | 1.81e-04 | 93 |
| GO:003021812 | Liver | HCC | erythrocyte differentiation | 73/7958 | 120/18723 | 3.82e-05 | 3.80e-04 | 73 |
| GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
| GO:004887222 | Liver | HCC | homeostasis of number of cells | 147/7958 | 272/18723 | 7.48e-05 | 6.70e-04 | 147 |
| GO:005507612 | Liver | HCC | transition metal ion homeostasis | 81/7958 | 138/18723 | 8.87e-05 | 7.72e-04 | 81 |
| GO:0042168 | Liver | HCC | heme metabolic process | 30/7958 | 42/18723 | 1.40e-04 | 1.13e-03 | 30 |
| GO:00330131 | Liver | HCC | tetrapyrrole metabolic process | 39/7958 | 59/18723 | 2.14e-04 | 1.63e-03 | 39 |
| GO:00067781 | Liver | HCC | porphyrin-containing compound metabolic process | 33/7958 | 49/18723 | 3.86e-04 | 2.62e-03 | 33 |
| GO:004691611 | Liver | HCC | cellular transition metal ion homeostasis | 67/7958 | 115/18723 | 4.64e-04 | 3.08e-03 | 67 |
| GO:0042440 | Liver | HCC | pigment metabolic process | 51/7958 | 84/18723 | 5.74e-04 | 3.65e-03 | 51 |
| GO:00000411 | Liver | HCC | transition metal ion transport | 59/7958 | 105/18723 | 3.18e-03 | 1.47e-02 | 59 |
| GO:0006783 | Liver | HCC | heme biosynthetic process | 19/7958 | 27/18723 | 3.18e-03 | 1.47e-02 | 19 |
| GO:0006779 | Liver | HCC | porphyrin-containing compound biosynthetic process | 21/7958 | 31/18723 | 4.01e-03 | 1.76e-02 | 21 |
| GO:0033014 | Liver | HCC | tetrapyrrole biosynthetic process | 21/7958 | 31/18723 | 4.01e-03 | 1.76e-02 | 21 |
| GO:0046148 | Liver | HCC | pigment biosynthetic process | 37/7958 | 62/18723 | 4.73e-03 | 2.02e-02 | 37 |
| GO:003526421 | Liver | HCC | multicellular organism growth | 70/7958 | 132/18723 | 9.29e-03 | 3.57e-02 | 70 |
| GO:0015886 | Liver | HCC | heme transport | 9/7958 | 11/18723 | 9.51e-03 | 3.60e-02 | 9 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FLVCR1 | SNV | Missense_Mutation | rs766279883 | c.160N>T | p.Arg54Trp | p.R54W | Q9Y5Y0 | protein_coding | deleterious(0.02) | benign(0.17) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| FLVCR1 | SNV | Missense_Mutation | novel | c.949G>A | p.Glu317Lys | p.E317K | Q9Y5Y0 | protein_coding | tolerated(0.14) | benign(0.027) | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| FLVCR1 | SNV | Missense_Mutation | c.1173G>T | p.Trp391Cys | p.W391C | Q9Y5Y0 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| FLVCR1 | SNV | Missense_Mutation | c.805N>T | p.Leu269Phe | p.L269F | Q9Y5Y0 | protein_coding | tolerated(0.08) | benign(0.14) | TCGA-C8-A12O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FLVCR1 | deletion | Frame_Shift_Del | novel | c.416delA | p.Tyr139SerfsTer121 | p.Y139Sfs*121 | Q9Y5Y0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FLVCR1 | SNV | Missense_Mutation | novel | c.1148T>C | p.Val383Ala | p.V383A | Q9Y5Y0 | protein_coding | tolerated(0.17) | benign(0.088) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FLVCR1 | SNV | Missense_Mutation | novel | c.1641G>T | p.Leu547Phe | p.L547F | Q9Y5Y0 | protein_coding | tolerated_low_confidence(0.13) | benign(0.031) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
| FLVCR1 | insertion | Frame_Shift_Ins | novel | c.1413_1413+1insCAAAAGAAACTACCATCAGA | p.Ile472GlnfsTer39 | p.I472Qfs*39 | Q9Y5Y0 | protein_coding | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | ||
| FLVCR1 | insertion | Frame_Shift_Ins | novel | c.1413_1413+1insCAAAAGAAACTACCATCAGAGT | p.Ile472GlnfsTer27 | p.I472Qfs*27 | Q9Y5Y0 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| FLVCR1 | SNV | Missense_Mutation | c.1286T>G | p.Phe429Cys | p.F429C | Q9Y5Y0 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |